Summary
Eli Lilly & Company reported a strong first quarter for 2008, with net sales increasing by 14% to $4.81 billion compared to the same period in 2007. This growth was primarily driven by key products like Cymbalta, Cialis, Humalog, Alimta, and Gemzar. Net income saw a significant surge, more than doubling to $1.06 billion from $508.7 million in the prior year, largely due to a substantial $210.3 million income tax benefit from the resolution of a significant portion of an IRS audit. Diluted earnings per share also increased to $0.97 from $0.47 in the first quarter of 2007. The company also highlighted progress in its product pipeline and business development initiatives, including submissions for new indications and approvals in various markets. However, the company also incurred charges related to the termination of its AIR Insulin program and acquired in-process research and development, which impacted earnings. Investors should note the ongoing legal proceedings, particularly related to Zyprexa, which continue to present potential material impacts to future results, though the company believes it will prevail in these matters.
Key Highlights
- 1Net sales increased by 14% to $4.81 billion for the first quarter of 2008, driven by strong performance in key products.
- 2Net income more than doubled to $1.06 billion ($0.97 EPS) compared to $508.7 million ($0.47 EPS) in Q1 2007.
- 3A significant $210.3 million income tax benefit was recognized due to the resolution of a substantial portion of an IRS audit for tax years 2001-2004.
- 4The company incurred $145.7 million in asset impairments, restructuring, and other special charges, primarily related to the termination of the AIR Insulin program.
- 5Acquired in-process research and development charges amounted to $87.0 million, related to a licensing agreement with BioMS Medical Corp.
- 6Worldwide sales growth was 14%, with U.S. sales up 10% and international sales up 18%.
- 7The company continues to actively manage significant ongoing legal and regulatory matters, particularly concerning Zyprexa, with potential for material impact on future results.